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Dementia in old age – diagnostics, differentiation and current 
therapeutic management proposition
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Abstract
The disorder of higher functions of the core is characteristic of dementia, which often affects old people. It is mainly caused by Alz-
heimer’s disease (AD), vascular dementia (VaD), frontotemporal dementia and dementia with Lewy’s Bodies. Etiology of AD is still 
unknown. The most important risk factor are APOE 4 gene, age, sex, short education period, jobs that do not require intellectual 
activity and dementia among family members. The main pathomorphological changes consist in the presence of senile plaques and 
neurofibrillary tangles, whereas pathophysiological changes consist in disorders in cholinergic system. AD manifests itself in the insi-
dious onset, a slow course of the disease, memory, spatial orientation and behavioural disorders, aphasia, apraxia, agnosia, dissomnia, 
difficulties in getting dressed and practising personal hygiene, and later on hallucinations, delusions, incontinent sphincters, increas-
ing weakness and lack of mobility finally resulting in infections and decubitus ulcers. Vascular dementia is generally caused by cere-
bral ischaemia. The main risk factors include age, sex, hypertension, level of education, smoking, diabetes, and hypercholesterolae-
mia. VaD differs from AD with a sudden onset, an irregular course of disease, criticism and mood depression. It is more frequent in 
men. Dementia with Lewy Bodies takes a course with intensified extrapiramidal disorders, whereas frontotemporal dementia – with 
behavioural ones. In diagnosing dementia the most important are an interview, laboratory, neuropsychological, CT and MRI investi-
gations. In AD treatment cholinesterase inhibitors are most often used while in VaD – antiarteriosclerotic drugs and those improving 
cerebral circulation. Long-lasting rehabilitation is playing an increasingly significant role in treating these groups of patients.
Słowa kluczowe
choroba Alzheimera, otępienie czołowo-skroniowe, otępienie naczyniopochodne, otępienie z ciałami Lewy’ego, farmakoterapia, re-
habilitacja
Streszczenie
Otępienie jest zaburzeniem wyższych funkcji korowych często występującym w starości, spowodowanym chorobą Alzheimera (AD), 
otępieniami: naczyniowym (VaD), z ciałami Lewy´ego lub czołowo-skroniowym. Etiologia AD jest nadal nieznana. Najważniejszymi 
czynnikami predysponującym są: gen APOE 4, wiek, płeć, krótki okres edukacji, zawód nie wymagający aktywności umysłowej i wy-
stępowania otępienia w rodzinie. Główne zmiany patomorfologiczne polegają na obecności w mózgu płytek starczych oraz zwyrod-
nienia włókienkowego, a patofizjologiczne na zaburzeniu w układzie cholinergicznym. AD objawia się podstępnym początkiem, po-
wolnym przebiegiem, zaburzeniami pamięci, orientacji i zachowania, afazją, apraksją, agnozją, przestawieniem rytmu dobowego snu, 
trudnościami w ubieraniu i utrzymywaniu higieny. Później występują halucynacje, urojenia, nietrzymanie zwieraczy, postępujące osła-
bienie, którego skutkiem jest leżący tryb życia, dołączają się infekcje i odleżyny. VaD spowodowane jest najczęściej niedokrwieniem. 
Do czynników ryzyka tego otępienia należą głównie: wiek, płeć, nadciśnienie, niski poziom wykształcenia, nikotynizm, cukrzyca, hi-
percholesterolemia. W VaD częściej niż w AD obserwuje się nagły początek, skokowy przebieg, zachowany krytycyzm, obniżony na-
strój. Występuje częściej u mężczyzn. Otępienie z ciałami Lewy’ego przebiega z nasilonymi zaburzeniami pozapiramidowymi, nato-
miast czołowo-skroniowe z zaburzeniami behawioralnymi. W diagnostyce otępień najważniejsze są: wywiad, badania laboratoryjne, 
neuropsychologiczne oraz CT lub MRI w celu wykluczenia innych przyczyn zaburzeń. W leczeniu AD stosuje się głównie inhibitory 
acetylocholinesterazy, a w VaD leki poprawiające krążenie mózgowe oraz przeciwmiażdżycowe. Coraz ważniejszą rolę odgrywa dłu-
gotrwały proces rehabilitacji.
Definition
According to the World Health Or-
ganisation, dementia (lat. dementia) 
is defined as a syndrome induced by 
cerebral disease, usually chronic or 
progressive, characterised clinically 
by numerous disturbances of cortical 
cognitive functions such as memory, 
thought, orientation, comprehension, 
Article from the Chair of Internal Medicine and Gerontology at Jagiellonian University Medical College, Cracow, Poland
Received 21.12.2004; accepted 05.10.2005
14
counting, learning ability, language 
and judgement. The above cognitive 
functions disturbances are frequent-
ly accompanied or even preceded by 
emotional, behavioural and motiva-
tional disturbances.
Prevalence
The prevalence of dementia increases 
with age from less than 1% in the age 
range of 60–64 years to almost 40% 
at the age of over 90 years, and the in-
dex of this process doubles every 5.1 
years. The prevalence of dementia in 
the whole geriatric population ranges 
approx. 2–10%1,2.
A study on dementia in Poland con-
ducted in the Warsaw population de-
termined its prevalence as 5.7% in 
people aged 65–84 years3. In the pop-
ulation of villages and little towns, the 
prevalence of dementia was 3.5% for 
Alzheimer’s disease (AD) and 3.6% 
for vascular dementia (VaD)4. During 
the late senility (75 years and older), 
dementia was suspected in 23.6% of 
persons in the city population and in 
17.8% in the village population, more 
frequently in women5.
The most frequent cause of demen-
tia in the western societies is Alzheim-
er’s disease constituting approx. 50–
70% of all cases of this syndrome. 
Its prevalence is estimated for 1.9 to 
5.8% in the geriatric population1. The 
majority of reports indicate its increas-
ing incidence in women. Prevalence of 
AD doubles above 65 years of age ev-
ery 4.5 year6, and the age is consid-
ered the best established risk factor 
for this disease.
Vascular dementia is the second 
most frequent dementia type after AD 
in the European and North American 
countries (with a prevalence of 12–
30%), and the most frequent in some 
Far East populations (India, Japan, 
China, Russia). Its prevalence dou-
bles every 5.3 years7,8.
The true prevalence of the fron-
to-temporal dementia (FTD) has not 
been precisely determined. Currently, 
it is assumed that in the elderly, it is 
the fourth most frequent, and in the 
younger people even the second most 
frequent cause of dementia after AD9.
Dementia with Lewy bodies (DLB), 
rarely diagnosed clinically, constitutes, 
according to some neuropathological 




The most frequent primary degener-
ative disease of the brain leading to 
dementia was described in 1906 by 
a German neurologist, Alois Alzheim-
er. Precise data on the prevalence of 
this disease in Poland are unavailable. 
According to various sources, at least 
250000 – 400000 people suffer from 
this disease, which indicates that in 
each average family physician’s area, 
there are approx. 30 persons with AD. 
A significant number of cases of the 
disease are undiagnosed and untreat-
ed or treated inappropriately10.
A biological factor, the apolipo-
protein E gene (the APOE 4 gene) 
localised to the chromosome 19, re-
ferred to as “susceptibility gene” (8-
fold increased risk of the disease) is 
considered to be the most important 
factor predisposing to AD. In cas-
es of the presence of two e4 alleles 
(APOE4/4), the disease occurs earli-
er and progresses more rapidly, when 
there is one e4 allele – the progression 
is slower. Apolipoprotein E is present 
in the senile plaques, neurones and 
amyloid deposits, participates in their 
aggregation, and regulates the density 
of synapses.
Mutations of the b-amyloid pre-
cursor protein (APP) gene (chromo-
some 21), the presenilin I gene (chro-
mosome 14) and the presenilin II 
gene (chromosome 1) play an impor-
tant role in the pathology of demen-
tia in some patients (10–15% of AD 
cases)11,12.
The following features are also con-
sidered to be important risk factors 
for AD: age, sex (the disease is more 
frequent in women), short educa-
tion period, jobs not requiring men-
tal activity, family history of demen-
tia syndromes, head trauma. Recent-
ly, an important role of cardiovascular 
risk factors in AD aetiology has been 
noticed12.
Presence of two changes in the cere-
bral tissue is considered to be the ba-
sis for pathological diagnosis of AD: 
senile plaques and neurofibrillary tan-
gles. Senile plaques are extracellular 
changes of approximately 20–150 mi-
crons size being primarily b-amyloid 
deposits – a protein of a 39–43 ami-
no acid-chain, formed from the amy-
loid precursor protein with the par-
ticipation of secretases. The plaques 
occur in various forms of “maturity”, 
they are built up of a centrally located 
amyloid core surrounded by microglia 
and astroglia. They contain presenil-
in I and II, apolipoprotein E (ApoE) 
produced by the astrocytes and mac-
rophages. Amyloid, via its toxic effects 
on the neurones, induces slowing of 
axonal transport and disturbances 
of phosphorylation of another pro-
tein typical for AD – the tau protein, 
which in turn contributes to the for-
mation of the other change character-
istic for this disease – neurofibrillary 
tangles. In the ultrastructural evalua-
tion, this degeneration has a form of 
paired helical filaments comprising in 
80% the excessively phosphorylated 
tau protein (normally, one molecule 
of this protein contains 2–3 phosphate 
groups, in Alzheimer’s disease – 8–
10). Hyperphosphorylation induces 
changes in the structure of microtu-
bules, which subsequently contribute 
to greater hydrophilic properties of 
the cytoplasm and neuronal damage. 
This pathology can also occur in other 
neurodegenerative diseases; however, 
most frequently accompanies AD, and 
the number of changes correlates with 
clinical symptoms and a reduction in 
the number of neurones11,12. Less spe-
cific changes are also observed in the 
brains of patients with dementia of Al-
zheimer-type, such as: diffuse amyloid 
deposits in the walls of cerebral ar-
teries, neuronal reduction, reduction 
in the number of synapses, increased 
microglia and astroglia reactivity and 
diffuse white matter changes.
Disturbance of cholinergic trans-
mission with a reduction in cholin-
ergic neurones number and in cho-
line acetyltransferase activity with 
concomitant increase in cholinester-
ase activity (the enzyme decompos-
ing acetylcholine) are considered to be 
most important in the pathophysiolo-
gy of Alzheimer’s disease. Apo E ex-
erts a significant effect on the func-
tion and integrity of the cholinergic 
system. In the pathophysiology of AD, 
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disturbances of other neurotransmit-
ters (serotonergic, dopaminergic, glu-
tamatergic) are also emphasised.
In the last years, the role of the dis-
turbed lipid metabolism, via the ApoE 
– the main lipoprotein of the central 
nervous system – in the pathophysiol-
ogy of dementia of this type has been 
denoted. Increased cholesterol level 
induces acceleration of b-amyloid ag-
gregation and hyperphosphorylation 
of the tau protein13.
Insidious onset, slow progression 
(faster in younger patients), distur-
bances of memory – originally re-
cent, then also remote, aphasia, ori-
entation and behavioural disturbances 
are typical for Alzheimer’s disease. At 
the beginning, decreased mood, rarer 
– depression, with preserved criticism 
can occur; in the later course of the 
disease, dysphoria, increased mood, 
sometimes jocular attitude or mania 
associated with anxiety, lack of con-
centration and compulsive walking 
are more frequent12. Sleep disturbanc-
es are usually present in the later stage 
of the disease. Reversal of the circa-
dian rhythm with drowsiness during 
the day and arousal during the night 
(sunset syndrome) is typical. Perma-
nent signs of the disease also include: 
apraxia, agnosia, difficulties in dress-
ing-up and maintenance of personal 
hygiene. In the advanced stage of the 
disease, sphincter dysfunction, halluci-
nations, delusions, worsening of gait, 
progressive weakness, stiffening of 
the trunk with aggravation of extra-
pyramidal signs occur. In the terminal 
phase of the disease, patients are un-
able to move independently, later even 
despite assistance. As a consequence 
of this state, patients remain in bed, 
muscle atrophy and limb contractures 
occur, decubitus, urinary and respira-
tory tract infections appear. The lat-
ter three complications constitute the 
most frequent causes of death in pa-
tients with AD dementia11,12.
For the staging of Alzheimer’s dis-
ease, the GDS (Global Deterioration 
Scale according to Reisberg – table 1) 
is often used in a clinical setting14. It 
is a seven-point scale of patient’s func-
tioning based partially on the histo-
ry taken from the family and caregiv-
ers and on the examination of the pa-
tient. In the first stage of the disease 
according to the GDS, no cognitive 
decline is present (pre-clinical phase), 
in the second – only very mild dis-
turbances of recent memory are pres-
ent, depression and conflicts with pa-
tient’s environment can occur. In the 
third period – of mild cognitive im-
pairment – loss of the ability to work 
and of full, independent functioning 
in the environment (inability to cope 
with money-related issues, to safe-
ly drive, to use phonebook and plan 
trips and shopping) occur. In the next 
stage (mild dementia), there are dis-
turbances of orientation in time and 
space, hygienic negligence, loss of sen-
sation of risk and emotional irritabil-
ity and instability. In the fifth phase 
of the disease (moderate dementia), 
difficulties in sphincter control oc-
cur, compulsive walking and behav-
ioural perseverations are present. In 
the next stage (moderately severe de-
mentia), further disturbances add to 
the clinical picture: difficulties in mo-
tion (falls, shuffling gait, holding on to 
the household facilities, difficulties in 
gait initiation and standing-up), eating 
with fingers, aggravated speech dis-
turbances (word perseverations, lim-
ited vocabulary, difficulties in speech 
comprehension, sometimes echolalia) 
and delusions. In the terminal stage 
of the disease (severe dementia), the 
abilities of communication and loco-
motion are lost; there is a complete 
dependence on the caregiver (neces-
sity of feeding); uncontrolled behav-
iours (e.g. persistent cry) and neuro-
logical signs (parkinsonism, frontal re-
lease signs, convulsions can occur) are 
present as well as complications add 
to the clinical picture.
It is assumed that the average dura-
tion of the disease, starting with the 
time of its diagnosis, is approx. 8–14 
years. In clinical practice, diagnosis of 
the disease is made no earlier than in 
the third or fourth stage, which cor-
responds to a shorter disease course, 
of approximately 5–7 years.
The Mini Mental State Examina-
tion (MMSE) is most frequently used 
as a screening test for dementia15.
For the diagnosis of the type and 
degree of dementia, it is necessary, 
apart from the history and physical 
examination, to perform laboratory 
studies (basic tests, thyroid gland hor-
mones, vitamin B12) to exclude other 
(mainly internal diseases-associated) 
causes of cognitive function distur-
bances (anaemia, especially associated 
with B12 deficiency, hypothyroidism, 
respiratory, heart, renal and hepatic 
failure-associated encephalopathies, 
electrolyte disturbances, hypoglycae-
mia, chronic drugs and alcohol abuse). 
Neuropsychological and neurological 
evaluation must be taken into account 
for the diagnosis of AD, as well as CT 
and MRI studies must be performed 
to rule out causes of dementia oth-
er than AD (tumours, stroke, subdu-
ral haematoma, normotensive hydro-
cephalus). In the AD evaluation (but 
not in common clinical practice), posi-
tron emission tomography, cerebrospi-
nal fluid examination (with b-amyloid 
and tau protein assay), assessment of 
the apolipoprotein E gene polymor-
phism are also used11,12.
Dementia is most commonly diag-
nosed according to the criteria of the 
American Psychiatric Society – the 
DSM IV11,12. Memory disturbances 
Table 1
Global Deterioration Scale – GDS14
Level Symptoms
1. No cognitive decline disease diagnosed accidentally
2. Very mild cognitive 
decline
disturbances of recent memory
3. Mild cognitive 
impairment
getting lost in travel, difficulties in shopping
4. Mild dementia disturbances in orientation in time and space
5. Moderate dementia non-independent in self-service
6. Moderately severe 
dementia
incontinence, delusional behaviours
7. Severe dementia loss of speech, loss of psychomotor abilities, e.g. of 
gait, immobilisation in bed, complications
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and presence of at least one of the fol-
lowing cognitive disturbances: apha-
sia, apraxia, agnosia, executive func-
tions disturbances, constitute the basis 
of the diagnosis. The listed cognitive 
dysfunctions elicit significant difficul-
ties in the social or professional life 
and there is a decrease in the level of 
functioning in comparison to the lev-
el previously observed in the patient. 
For the diagnosis of AD according to 
these criteria, it is also necessary to 
rule out other causes of cognitive dys-
function. Other criteria, according to 
the ICD–10, also consider disturbanc-
es duration longer than 6 months as 
a factor increasing the probability of 
AD diagnosis.
When establishing the diagnosis of 
Alzheimer’s disease, other above men-
tioned causes of cognitive disturbanc-
es as well as depression and acute dis-
turbances of consciousness (delirium) 
should be excluded. The most impor-
tant features differentiating Alzheim-
er’s disease from vascular dementia 
include: progressive course in AD, 
without somatic complaints, absence 
of pronounced neurological signs and 
focal changes in the CT scans. Women 
suffer from AD four times more fre-
quently than men.
Vascular dementia
This disease primarily refers to men 
and is characterised by a stepwise 
progression, with presence of somat-
ic complaints and neurological signs. 
In CT scans, focal changes in the brain 
are observed11,12. This form of de-
mentia occurs most often as a result 
of ischaemic, less frequently haem-
orrhagic or inflammatory, changes. 
Multi-infarct dementia (cortical) is 
the most frequent form of vascular de-
mentia. Much rarer, vascular demen-
tia may manifest as subcortical demen-
tia (Binswanger’s disease) or demen-
tia associated with a strategic stroke 
(localised in the thalami, in the base 
of the forebrain, in the caudate nuclei 
or in the angular gyrus of the domi-
nant hemisphere). Clinically, cases of 
mixed forms of various VaD types as 
well as their coexistence with AD are 
frequently observed16.
The features considered to be the 
most important risk factors for VaD 
include age, male sex, low educational 
level, vascular risk factors for athero-
sclerosis: arterial hypertension, nico-
tine smoking, previous myocardial in-
farctions, diabetes mellitus, hypercho-
lesterolemia, as well as increased ho-
mocysteine level and presence of anti-
phospholipid antibodies. Prevalence 
of vascular dementia after cerebral 
stroke ranges from 9.2% to 56.3%16.
Fronto-temporal dementia
This form of dementia is a neurode-
generative process in the brain with 
dominant behavioural disturbanc-
es and personality change (the fron-
tal variant) or, less frequently, with 
speech disturbances (the temporal 
variant). Principal symptoms of FTD 
include: slow onset and progressive 
course, early occurrence of social be-
havioural disturbances, absent self-
criticism and presence of emotional 
dullness. The following features con-
firm the diagnosis: behavioural and 
speech disturbances, frontal release 
signs, bradykinesia, tremor and mus-
cle rigidity, neuropsychological eval-
uation demonstrating frontal deficits 
with the absence of profound memo-
ry disturbances. Neuroimaging stud-
ies reveal atrophy of the frontal lobes 
and/or of the anterior parts of the 
temporal lobes. There is a family his-
tory in approximately 30–50% of cas-
es. In the clinical praxis, this dementia 
is rarely diagnosed, most frequently as 
a form of AD9.
Dementia with Lewy bodies
This type of dementia is associated 
with psychopathological disturbanc-
es (psychotic syndromes and behav-
ioural disturbances), with accompa-
nying dizziness, falls and parkinso-
nian features. It is three times more 
frequent in men. For the diagnosis of 
probable DLB, two symptoms and for 
the possible DLB, one of the follow-
ing symptoms is required:
– fluctuations of cognitive dysfunc-
tion with particularly pronounced 
attention disturbances,
– recurring visual hallucinations that 
are clear and detailed,
– parkinsonian signs.
The diagnosis of DLB is favoured by: 
recurrent falls, syncope, transient con-
sciousness disturbances, hypersensitiv-
ity to neuroleptics, systematic delu-
sions and hallucinations17,18.
In the differential diagnosis of AD 
with depression, establishing the di-
agnosis of AD is favoured by: insidi-
ous onset, progressive course, recent 
memory disturbances, night-time 
worsening, labile mood, absent criti-
cism. Conversely, the onset of depres-
sion is usually acute, the course non-
progressive, disturbances of recent 
and remote memory are similar, ag-
gravation of symptoms occurs in the 
morning, the mood is stabile and the 
criticism preserved19.
Delirium
Delirium (lat. delirium) is an acute ce-
rebral syndrome manifested as impair-
ment of the brain function and cogni-
tive dysfunction induced by dehydra-
tion, electrolyte disturbances, hypox-
ia, hypoglycaemia, intoxication (par-
ticularly with drugs). Therefore, the 
time criterion is crucial for the differ-
ential diagnosis of dementia. Possible 
causes of delirium in the elderly may 
include almost all somatic and psychi-
atric diseases, a change in the environ-
ment, stress, drugs, dehydration and 
alcohol. The most frequent symptoms 
of delirium are acute disturbances of 
consciousness, concentration, orien-
tation in time and space, psychomo-
tor agitation, perception disturbanc-
es, impairment of abstract thinking, 
illusions and hallucinations, most fre-
quently visual19.
Treatment and rehabilitation
As cholinergic system disturbanc-
es are the early and important bio-
chemical change in Alzheimer’s dis-
ease, use of cholinesterase inhibitors 
has been most justifiable in the phar-
macotherapy of AD20. There are cur-
rently three drug substances autho-
rised for marketing in Poland: done-
pezil (Aricept, Yasnal, Donepex, Cogi-
ton), rivastigmine (Exelon) and galan-
tamine (Reminyl).
In the last years, memantine (Ebixa, 
Axura) – a low affinity antagonist of 
NMDA receptors inhibiting the ex-
cessive glutamatergic system activity 
observed particularly in the advanced 
stage of Alzheimer’s disease – has 
been introduced to the treatment of 
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this disease. Neuroprotective agents 
(piracetam, selegiline – a MAO-B in-
hibitor, antioxidants – Vit. C, E, B6, 
trimetazidine), preparations improv-
ing cerebral circulation (nicergoline, 
vinpocetine, pentoxyphyllin, gingko 
biloba extract) are also used in the 
therapy (although their efficacy in AD 
has not been univocally proven). Of 
the above preparations, mainly sele-
giline and vitamin E are worth atten-
tion, because the disease progression 
modulating effect was demonstrated 
for these agents in a large randomised 
study21. However, there is no explicit 
evidence for the effectiveness of add-
ing vitamin E to cholinesterase inhib-
itors in AD therapy. Results on the ef-
ficacy of treatment of cognitive defi-
cits in Alzheimer’s with gingko biloba 
extract preparations are also contra-
dictory.
In the advanced dementia, patients 
primarily require treatment of agita-
tion and sleep disturbances (neuro-
leptics are most often used), although 
currently, there is also an opinion that 
at this stage of the disease, cholines-
terase inhibitors may be also effec-
tive, as they not only improve cogni-
tive function, but also have positive 
effects on behavioural disturbances in 
AD20,22.
In VaD management, primary and 
secondary prevention of atherosclero-
sis is most important. Use of prepara-
tions improving cerebral blood flow 
has not been unequivocally proven to 
have beneficial therapeutic effects. Use 
of cholinesterase inhibitors may also 
be justified in VaD, as cholinergic defi-
cit is also present in this disease16.
The therapy of fronto-temporal de-
mentia primarily involves symptomat-
ic treatment. In many cases, selective 
serotonin reuptake inhibitors may be 
useful because of the reduction of se-
rotonergic transmission, and in cases 
of agitation and aggression – neuro-
leptics may be administered9.
Dementia with Lewy bodies is symp-
tomatically treated with cholinesterase 
inhibitors and levodopa preparations. 
Hypersensitivity to neuroleptics and 
paradoxical reaction to benzodiaze-
pines in this form of dementia should 
be born in mind22.
Apart from the pharmacotherapy, 
non-pharmacological methods play 
an important role in the treatment of 
dementias. They aim at preservation 
of the activity and independent self-
service, training memory and orien-
tation, reducing stress and improv-
ing quality of life. Education of the 
caregivers and formation of support 
groups in home-care and in day-care 
centres are particularly emphasised23.
At each stage of the disease, phys-
ical rehabilitation, adjusted to actual 
patient’s abilities, improving physical 
agility and intellectual skills (also by 
influencing cerebral blood flow) and 
reducing emotional tension and anx-
iety is recommended24. Appropriate-
ly selected exercises for the patients 
with dementia ensure maintenance 
of good physical fitness by reinforc-
ing muscle strength, increasing bone 
mass, counteracting balance distur-
bances and preventing falls. More-
over, mild tiredness following physi-
cal effort facilitates falling asleep and 
improves sleep quality. Physical exer-
cises also stimulate intestinal motili-
ty thus preventing chronic constipa-
tion. They also alleviate and reduce 
the frequency of such symptoms as 
anxiety, agitation and wandering. Fi-
nally, performance of the exercises by 
the patient together with his caregiv-
er favours maintaining the contact be-
tween them and diminishes the inten-
sity of anxiety and depression symp-
toms in the patient24.
In each phase of the disease, the aim 
of the rehabilitation is to take maxi-
mum advantage of patient’s potential 
abilities of self-service, to maintain in-
dependent functioning skills still not 
disturbed in the deterioration process 
(including hand exercises enabling in-
dependent eating and dressing-up, ex-
ercises of the pelvic muscles in order 
to maintain sphincter control), to pre-
vent falls, immobilisation in bed and 
aggravation of extrapyramidal distur-
bances resulting both from dementia 
itself and from undesirable effects of 
the drugs (neuroleptics). Finally, in the 
terminal stage of the disease, the goal 
of rehabilitation involves prevention 
of complications, primarily of decu-
bitus and infections.
In the studies by Arkin25, cogni-
tive functions deterioration was not 
observed during a 20-week observa-
tion, despite the progressive charac-
ter of the disease, in any of the AD 
patients, in whom physical exercises 
(short warm-up, stretching exercises, 
treadmill and cycloergometer train-
ing, exercises with weights as well 
as a 20-minute walk) were conduct-
ed regularly twice a week. A notice-
able improvement of general phys-
ical agility and mood was observed. 
In Andersen’s26 observations, increas-
ing the activity of every-day living also 
ameliorated dementia patients’ qual-
ity of life.
Meta-analysis of 30 studies on the 
significance of physical rehabilita-
tion in patients with dementia (a to-
tal of 2020 patients above 65 years 
of age) explicitly proves that individ-
ually adjusted physical exercise pro-
gramme improves cognitive function 
and has beneficial effects on behav-
ioural disturbances at each stage of 
the disease27.
In dementia, other non-pharmaco-
logical forms of therapy are also rec-
ommended, such as: memory train-
ing, singing, music therapy, therapeu-
tic fine arts and dancing. The aim of 
these activities is to improve func-
tioning of memory, orientation in 
time and space and patient’s quali-
ty of daily living. Recently, a signifi-
cant role of the so-called reminiscence 
therapy in dementia has been empha-
sised, which involves evoking remi-
niscences using stimulating materials 
(objects, sounds, paintings, pictures, 
smells – the so-called memory an-
chors). Some centres for AD patients 
therapy offer “rooms of reminiscenc-
es” arranged like typical flats as of be-
fore several decades, where, in a ther-
apeutic group, patients are provoked 
to recall and share their memories. It 
was demonstrated that this form of 
therapy alleviates behavioural distur-
bances as well as has a better effect on 
patients’ activity and general feeling as 
compared to the standard programme 
of simple exercises28.
Appropriately conducted, compre-
hensive, pharmacological and non-
pharmacological therapy, adjusted to 
actual clinical status, where it is im-
portant to avoid hyperprotectiveness 
and changes in environment (includ-
ing unjustified hospitalisations), plays 
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